Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
MBX Biosciences’ $187.7 Million IPO
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
FogPharma’s $178 Million Series D Financing
Goodwin Procter advised FogPharma® on the deal. FogPharma® announced its $178 Million Series D financing. FogPharma is a biopharmaceutical company pioneering a new class of precision...
CathWorks’ Acquisition Option Agreement and Co-promotion Agreement with Medtronic
Goodwin Procter advised CathWorks on the deal. CathWorks announced its acquisition option agreement and co-promotion agreement with Medtronic (NYSE: MDT). Under the acquisition option agreement, Medtronic will...
LifeMine Therapeutics’ $175 Million Series C Financing
Goodwin advised LifeMine Therapeutics on the deal. LifeMine Therapeutics announced its completion of a $175 million Series C financing. LifeMine Therapeutics is reinventing drug discovery by mining...
Janssen Pharmaceuticals’ Acquisition of Anakuria Therapeutics
Goodwin Procter advised Navitor Pharmaceuticals on the deal. Privately held Navitor Pharmaceuticals, LLC (“Navitor”), announced that Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies...
Gandeeva’s $40 Million Series A Funding
Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures,...
Korro Bio’s $116 Million Series B Financing
Goodwin advised Korro Bio on the deal. Korro Bio, Inc. announced its $116 million Series B financing. Korro is an RNA editing company focused on discovery...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Intellia Therapeutics’ $690 Million Underwritten Public Offering
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
Neuroelectrics’ $17.5 Million Series A Financing
Goodwin Procter LLP advised Neuroelectrics on the deal. Neuroelectrics announced its $17.5 million Series A financing led by Morningside Ventures. Neuroelectrics is developing a therapeutic platform that...
Aura Biosciences’ $80 Million Financing Round
Goodwin Procter LLP advised Aura Biosciences on the deal. Aura Biosciences announced the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital...